Target intelligence / Profile preview

5'-Nucleotidase (5'-NT)

Target
5'-NT
Molecular classification
Enzyme, Phosphatase, Ectoenzyme (for membrane-bound forms)
01

Overview

5'-Nucleotidase is an enzyme that catalyzes the hydrolysis of phosphate groups from nucleoside monophosphates at the 5' position, producing corresponding nucleosides and inorganic phosphate[2][4]. It exists both as a soluble cytoplasmic enzyme involved in nucleotide metabolism and as a membrane-bound ectoenzyme—most notably known as CD73—which plays a key role in generating extracellular adenosine from AMP[2][6]. This activity regulates purinergic signaling with broad implications for immune modulation, vascular function, inflammation control, and cancer biology[1][2][6]. The enzyme has wide substrate specificity but primarily acts on AMP; its activity can influence resistance mechanisms against certain chemotherapeutic agents by dephosphoryting active drug metabolites[5].

Other names
Ecto-5'-nucleotidaseCD73 (for the membrane-bound form)EC 3.1.3.55′-NTAMPase (in some contexts)
02

Mechanism of action

Drugs targeting this enzyme typically act as inhibitors to block the conversion of AMP to adenosine, thereby reducing immunosuppressive signaling mediated by adenosine in the tumor microenvironment or inflamed tissues.

03

Biological functions

Nucleotide metabolismHydrolysis of nucleoside monophosphates to nucleosides and phosphateRegulation of extracellular adenosine levelsModulation of purinergic signaling pathways
04

Disease associations

Cancer (tumor immune evasion, tumor progression)Inflammation (immunomodulation via adenosine production)Cardiovascular disease (regulation of vascular tone and thrombosis)
05

Safety considerations

Potential safety concerns include impaired tissue protection during hypoxia or ischemia due to reduced adenosine productionincreased risk of inflammation or autoimmunity from loss of immunoregulatory effectspossible off-target effects due to broad tissue distribution[2][6]
06

Biomarkers

CD73 expression is used as a biomarker for certain cancers and may be used for patient selection in clinical trials involving anti-CD73 therapies.

Beyond the preview

Go deeper on 5'-Nucleotidase (5'-NT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5'-Nucleotidase (5'-NT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call